Could a cannabis compound help teens with ADHD?

NCT ID NCT07592390

Recruiting now Symptom relief Sponsor: Universidade do Sul de Santa Catarina Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a cannabis compound called cannabigerol (CBG) can reduce ADHD symptoms like inattention and hyperactivity in teenagers. Sixty adolescents aged 12 to 17 who have not responded well to other treatments will receive either CBG oil or a placebo for 12 weeks. Researchers will track changes in symptoms, quality of life, and safety to see if CBG offers a new option for managing ADHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Contacts and locations

Locations

Universidade do Sul de Santa Catarina - UNISUL
RECRUITING

Tubarão, Santa Catarina, 88704900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.